Diabetes mellitus Posts - Page 2 of 105 on Medivizor
Navigation Menu

Diabetes mellitus Posts on Medivizor

Can high-frequency spinal cord stimulation provide relief to patients with painful diabetic nerve disease?

Can high-frequency spinal cord stimulation provide relief to patients with painful diabetic nerve disease?

Posted by on Mar 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the long-term impact of 10-kHz spinal cord stimulation (SCS) in patients with painful diabetic neuropathy (PDN; nerve disease) and refractory symptoms. The data supported the use of 10-kHz SCS for important, durable pain relief over 12 months in these patients. Some background Diabetic sensorimotor peripheral...

Read More

Comparing chiglitazar and sitagliptin effectiveness on glucose variations, insulin resistance and inflammation levels in patients with type 2 diabetes.

Comparing chiglitazar and sitagliptin effectiveness on glucose variations, insulin resistance and inflammation levels in patients with type 2 diabetes.

Posted by on Feb 13, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness of chiglitazar (Bilessglu) and sitagliptin (Januvia) on glycemic (blood glucose) variations, insulin resistance, and inflammation levels in patients with type 2 diabetes (T2D). The data showed that chiglitazar treatment was more effective at improving insulin resistance and inflammation compared...

Read More

Can physical activity affect glucose levels variations in patients with diabetes?

Can physical activity affect glucose levels variations in patients with diabetes?

Posted by on Feb 13, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effect of physical activity interventions on glycemic variability (GV; glucose levels variations) in patients with diabetes. The data showed that physical activity was associated with significantly reduced GV in these patients. Some background Physical activity has been shown to reduce hemoglobin A1c (the...

Read More

How beneficial is sodium-glucose co-transporter 2 inhibitor treatment for patients with type 2 diabetes mellitus and heart failure?

How beneficial is sodium-glucose co-transporter 2 inhibitor treatment for patients with type 2 diabetes mellitus and heart failure?

Posted by on Jan 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study reviewed the long-term use of sodium-glucose co-transporter 2 inhibitors (SGLT-2i) on the risk of mortality and hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) and heart failure (HF). The authors concluded that long-term use of SGLT-2 inhibitors can help to reduce mortality risk and HHF in...

Read More

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

Can combined therapy with sodium-glucose co-transporter 2 inhibitors and sulfonylureas affect the risk of hypoglycemia in patients with type 2 diabetes?

Posted by on Dec 31, 2021 in Diabetes mellitus | 0 comments

In a nutshell This review assessed the risk of hypoglycemia (dangerously low blood glucose) with the addition of sodium-glucose co-transporter 2 (SGLT-2) inhibitors to sulfonylureas in patients with type 2 diabetes (T2D). The authors concluded that this combination was associated with an increased risk of hypoglycemia. Some background...

Read More

Can anti-diabetic drug use affect fracture risk in patients with type 2 diabetes?

Can anti-diabetic drug use affect fracture risk in patients with type 2 diabetes?

Posted by on Dec 19, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the safety of anti-diabetic drugs in the risk of fractures based on available data from clinical trials. The data showed differences in associations between the use of anti-diabetic drugs and fracture risk. Some background Patients with type 2 diabetes (T2D) are more prone to bone fragility (increased bone...

Read More

Effectiveness and safety of tirzepatide compared to insulin degludec in patients with type 2 diabetes.

Effectiveness and safety of tirzepatide compared to insulin degludec in patients with type 2 diabetes.

Posted by on Oct 31, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness and safety of tirzepatide to insulin degludec (Tresiba) in patients with uncontrolled type 2 diabetes (T2D). The data showed that tirzepatide produced better blood glucose control and body weight improvements with reduced risk of hypoglycemia, compared to degludec in these patients. Some...

Read More

Improved changes in the eye in patients with type 2 diabetes using dapagliflozin compared to glibenclamide.

Improved changes in the eye in patients with type 2 diabetes using dapagliflozin compared to glibenclamide.

Posted by on Oct 31, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the change in central retinal thickness (CRT) by optical coherence tomography (OCT) in patients with type 2 diabetes (T2D) after 12 weeks of treatment with dapagliflozin (Farxiga) or glibenclamide (Diabeta). The authors concluded that CRT may improve with short-term use of dapagliflozin compared with...

Read More

Can exenatide affect kidney function in patients with type 2 diabetes mellitus that are overweight or obese?

Can exenatide affect kidney function in patients with type 2 diabetes mellitus that are overweight or obese?

Posted by on Oct 31, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the effect of exenatide (EXE; Byetta) on kidney function, obesity and glucose control in overweight or obese patients with type 2 diabetes (T2D). The data showed that EXE could assist in improving kidney function, glucose control, and inflammation after 24 weeks of treatment. Some background Diabetic...

Read More

Do insulin analogues differ in effectiveness and safety for the treatment of diabetes?

Do insulin analogues differ in effectiveness and safety for the treatment of diabetes?

Posted by on Oct 25, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effectiveness and safety of different long-acting and short-acting insulins for the treatment of patients with diabetes. The data supported the use of long-acting insulins instead of neutral protamine Hagedorn (NPH) insulin (Humulin N; Novolin N), as basal insulin for patients with type 2 diabetes (T2D). Some...

Read More

Do gliflozins or gliptins improve metabolic risk in patients with type 2 diabetes?

Do gliflozins or gliptins improve metabolic risk in patients with type 2 diabetes?

Posted by on Oct 17, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared canagliflozin (Invokana) to teneligliptin (Teneria) for patients with type 2 diabetes (T2D). It found that canagliflozin led to greater improvement in body weight and metabolic outcomes in these patients. Some background T2D is a health condition of the metabolism. T2D prevents the body from responding well to the...

Read More